Epizyme Inc. (NASDAQ: EPZM) shares tumbled on Tuesday after the U.S. Food and Drug Administration (FDA) announced a temporary hold on one of the firm’s clinical trials. Specifically, the agency issued a partial clinical hold affecting new enrollment of patients with genetically defined solid tumors and hematologic malignancies for the firm’s tazemetostat trials.
There are patients in the study who have not experienced disease progression and may continue to receive tazemetostat.
The partial clinical hold was initiated following a safety report, submitted by Epizyme to the FDA and other regulatory authorities, regarding a patient with advanced poorly differentiated chordoma in the company’s Phase 1 pediatric study who developed a secondary T-cell lymphoma.
At the time of the safety report, the patient had been on study for roughly 15 months and had achieved a confirmed partial response. This patient has now discontinued tazemetostat and is being treated for T-cell lymphoma.
T-cell lymphoma has been noted as a potential adverse event in tazemetostat study protocols and is included in the investigator’s brochure and the informed consent. More than 750 patients have been treated with tazemetostat to date, and this is the only case of secondary lymphoma that has been observed across the tazemetostat clinical program.
Robert Bazemore, president and CEO of Epizyme, commented:
Patient safety is of the utmost importance to Epizyme. We are working expeditiously with clinical trial investigators and regulatory authorities to initiate the appropriate steps to resume enrollment. Epizyme, along with our global investigator community, has been very encouraged by the clinical responses and tolerability of tazemetostat observed in pediatric and adult patients with hematological malignancies and solid tumors enrolled in our trials. We remain encouraged by the potential of tazemetostat to address the unmet needs of many patients living with cancer.
Shares of Epizyme were last seen down 14% at $13.15, with a consensus analyst price target of $25.40 and a 52-week range of $9.30 to $21.40.
24/7 Wall St.Are You Still Paying With a Debit Card?
The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.
Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!
Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!
Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.